Share Price and Basic Stock Data
Last Updated: October 9, 2025, 10:15 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Pharmaids Pharmaceuticals Ltd, a key player in the pharmaceutical industry, has a market capitalization of ₹184 Cr. The company has shown resilience in maintaining its market presence despite challenges. Analyzing the quarterly sales trends, we observe a consistent pattern of revenue growth, with a notable increase in annual sales over the past few years. However, the operating profit margin stands at -81.08%, indicating a need for cost management strategies to enhance profitability. It is crucial for Pharmaids to closely monitor expenses to improve operational efficiency and sustain growth.
Profitability and Efficiency Metrics
Despite facing a negative operating profit margin, Pharmaids Pharmaceuticals Ltd has maintained a ROE of 16.3% and a ROCE of 17.4%, which are relatively healthy figures within the pharmaceutical sector. The company’s interest coverage ratio of -6.06x raises concerns about its ability to meet interest obligations. Additionally, the negative net profit of -14 indicates potential financial strain. The Cash Conversion Cycle of -63 days suggests efficient management of working capital, but improvements in profitability are essential for long-term sustainability.
Balance Sheet Strength and Financial Ratios
Pharmaids Pharmaceuticals Ltd’s reserves amounting to ₹24 Cr demonstrate a stable financial base, although the borrowings of ₹39 Cr indicate a reliance on external funding. The Price-to-Book Value ratio of 4.08x suggests the stock may be overvalued compared to industry peers. The Interest Coverage Ratio of -6.06x highlights the company’s financial risk due to inadequate earnings to cover interest expenses. Strengthening the balance sheet by reducing borrowings and enhancing profitability is crucial for improving solvency.
Shareholding Pattern and Investor Confidence
With promoters holding 5.14% of the company’s shares and the majority held by the public at 94.87%, Pharmaids Pharmaceuticals Ltd exhibits a dispersed ownership structure. The absence of FII and DII holdings indicates limited institutional investor participation, potentially impacting market perception and liquidity. Changes in promoter holdings can signal shifts in confidence, influencing the stock’s valuation. Enhancing institutional interest through strategic partnerships could bolster investor confidence and market sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Pharmaids Pharmaceuticals Ltd should focus on diversifying revenue streams and enhancing operational efficiency to drive growth. Key growth drivers may include new product launches, strategic collaborations, and expansion into untapped markets. However, risks such as regulatory challenges, intense competition, and volatile market conditions could threaten future performance. Strengthening financial health, improving profitability, and fostering investor trust are critical for navigating uncertainties and achieving sustainable long-term success in the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Pharmaids Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,792.62 Cr | 1,163.29 | 50.86 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 5.81 | 4.73 | 5.24 | 4.71 | 4.77 | 6.66 |
| Expenses | 0.54 | 0.69 | 8.60 | 1.61 | 1.02 | 2.45 | 11.39 | 8.14 | 7.80 | 7.60 | 8.67 | 12.06 |
| Operating Profit | -0.54 | -0.69 | -8.60 | -1.61 | -1.02 | -2.43 | -5.58 | -3.41 | -2.56 | -2.89 | -3.90 | -5.40 |
| OPM % | -12,150.00% | -96.04% | -72.09% | -48.85% | -61.36% | -81.76% | -81.08% | |||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.41 | -0.26 | 0.76 | 0.12 | -0.07 | -0.06 | 0.00 | 0.13 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.77 | 0.26 | 0.33 | 0.48 | 1.01 | 1.20 |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.04 | 0.63 | 0.57 | 0.61 | 0.64 | 0.62 | 0.61 |
| Profit before tax | -0.55 | -0.70 | -8.60 | -1.21 | -1.29 | -1.73 | -6.86 | -4.31 | -3.56 | -4.01 | -5.40 | -7.17 |
| Tax % | 0.00% | 0.00% | -28.37% | 7.44% | -60.47% | -33.53% | -7.73% | -27.38% | -28.09% | -24.94% | -11.11% | -25.94% |
| Net Profit | -0.55 | -0.71 | -6.16 | -1.30 | -0.50 | -1.15 | -6.33 | -3.12 | -2.56 | -3.01 | -4.80 | -5.31 |
| EPS in Rs | -0.53 | -0.54 | -2.87 | -0.61 | -0.23 | -0.54 | -1.57 | -0.76 | -0.63 | -0.55 | -1.12 | -1.40 |
Last Updated: August 20, 2025, 5:15 am
Below is a detailed analysis of the quarterly data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6.66 Cr.. The value appears strong and on an upward trend. It has increased from 4.77 Cr. (Mar 2025) to 6.66 Cr., marking an increase of 1.89 Cr..
- For Expenses, as of Jun 2025, the value is 12.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.67 Cr. (Mar 2025) to 12.06 Cr., marking an increase of 3.39 Cr..
- For Operating Profit, as of Jun 2025, the value is -5.40 Cr.. The value appears to be declining and may need further review. It has decreased from -3.90 Cr. (Mar 2025) to -5.40 Cr., marking a decrease of 1.50 Cr..
- For OPM %, as of Jun 2025, the value is -81.08%. The value appears strong and on an upward trend. It has increased from -81.76% (Mar 2025) to -81.08%, marking an increase of 0.68%.
- For Other Income, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.09 Cr..
- For Interest, as of Jun 2025, the value is 1.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.01 Cr. (Mar 2025) to 1.20 Cr., marking an increase of 0.19 Cr..
- For Depreciation, as of Jun 2025, the value is 0.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.62 Cr. (Mar 2025) to 0.61 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -7.17 Cr.. The value appears to be declining and may need further review. It has decreased from -5.40 Cr. (Mar 2025) to -7.17 Cr., marking a decrease of 1.77 Cr..
- For Tax %, as of Jun 2025, the value is -25.94%. The value appears to be improving (decreasing) as expected. It has decreased from -11.11% (Mar 2025) to -25.94%, marking a decrease of 14.83%.
- For Net Profit, as of Jun 2025, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from -4.80 Cr. (Mar 2025) to -5.31 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.40. The value appears to be declining and may need further review. It has decreased from -1.12 (Mar 2025) to -1.40, marking a decrease of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:16 pm
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Sales | 4 | 0 | 15 | 19 | 21 |
| Expenses | 4 | 10 | 28 | 32 | 36 |
| Operating Profit | 0 | -10 | -13 | -13 | -15 |
| OPM % | 3% | -87% | -66% | -69% | |
| Other Income | 0 | 0 | 1 | 0 | 0 |
| Interest | 0 | 0 | 2 | 2 | 3 |
| Depreciation | 0 | 0 | 2 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 | -20 |
| Tax % | 0% | -24% | -24% | -22% | |
| Net Profit | 0 | -8 | -12 | -14 | -16 |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.70 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% |
Pharmaids Pharmaceuticals Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| TTM: | 102% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 70% |
| 3 Years: | 67% |
| 1 Year: | 53% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -20% |
| Last Year: | -16% |
Last Updated: September 5, 2025, 12:30 pm
Balance Sheet
Last Updated: June 16, 2025, 11:31 am
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 |
| Borrowings | 0 | 0 | 9 | 39 |
| Other Liabilities | 2 | 2 | 11 | 22 |
| Total Liabilities | 11 | 25 | 91 | 120 |
| Fixed Assets | 0 | 0 | 63 | 77 |
| CWIP | 0 | 2 | 7 | 5 |
| Investments | 0 | 3 | 0 | 0 |
| Other Assets | 11 | 19 | 21 | 39 |
| Total Assets | 11 | 25 | 91 | 120 |
Below is a detailed analysis of the balance sheet data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 35.00 Cr..
- For Reserves, as of Mar 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2024) to 24.00 Cr., marking a decrease of 13.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 9.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 30.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 120.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 91.00 Cr. (Mar 2024) to 120.00 Cr., marking an increase of 29.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Mar 2024) to 77.00 Cr., marking an increase of 14.00 Cr..
- For CWIP, as of Mar 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2024) to 5.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 18.00 Cr..
- For Total Assets, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 120.00 Cr., marking an increase of 29.00 Cr..
However, the Borrowings (39.00 Cr.) are higher than the Reserves (24.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Free Cash Flow | 0.00 | -10.00 | -22.00 | -52.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | |
| Inventory Days | 91 | 0 | 112 | 359 |
| Days Payable | 236 | 159 | 480 | |
| Cash Conversion Cycle | -21 | 17 | -63 | |
| Working Capital Days | -18 | -69 | -160 | |
| ROCE % | -64% | -26% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Diluted EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Cash EPS (Rs.) | -3.14 | -2.87 | -3.52 | 0.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Revenue From Operations / Share (Rs.) | 5.51 | 4.28 | 0.00 | 3.84 |
| PBDIT / Share (Rs.) | -3.59 | -3.50 | -4.61 | 0.14 |
| PBIT / Share (Rs.) | -4.28 | -3.98 | -4.62 | 0.13 |
| PBT / Share (Rs.) | -4.90 | -4.43 | -4.62 | 0.13 |
| Net Profit / Share (Rs.) | -3.83 | -3.36 | -3.52 | 0.14 |
| NP After MI And SOA / Share (Rs.) | -3.06 | -2.26 | -3.52 | 0.14 |
| PBDIT Margin (%) | -65.06 | -81.57 | 0.00 | 3.86 |
| PBIT Margin (%) | -77.61 | -92.99 | 0.00 | 3.63 |
| PBT Margin (%) | -88.85 | -103.37 | 0.00 | 3.56 |
| Net Profit Margin (%) | -69.44 | -78.36 | 0.00 | 3.68 |
| NP After MI And SOA Margin (%) | -55.41 | -52.72 | 0.00 | 3.68 |
| Return on Networth / Equity (%) | -18.16 | -11.05 | -33.64 | 1.67 |
| Return on Capital Employeed (%) | -16.56 | -17.61 | -44.09 | 1.64 |
| Return On Assets (%) | -8.99 | -8.72 | -30.72 | 1.30 |
| Long Term Debt / Equity (X) | 0.50 | 0.04 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.59 | 0.07 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.18 | 0.26 | 0.00 | 0.00 |
| Current Ratio (X) | 0.77 | 1.17 | 8.23 | 1.09 |
| Quick Ratio (X) | 0.35 | 0.85 | 8.23 | 0.72 |
| Inventory Turnover Ratio (X) | 1.13 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -6.06 | -7.86 | -2135.71 | 55.63 |
| Interest Coverage Ratio (Post Tax) (X) | -5.42 | -6.55 | -1631.24 | 54.05 |
| Enterprise Value (Cr.) | 271.01 | 182.39 | 34.01 | 12.44 |
| EV / Net Operating Revenue (X) | 13.94 | 12.07 | 0.00 | 3.16 |
| EV / EBITDA (X) | -21.42 | -14.79 | -3.44 | 81.73 |
| MarketCap / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| Price / BV (X) | 4.08 | 2.55 | 2.08 | 1.48 |
| Price / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| EarningsYield | -0.04 | -0.04 | -0.16 | 0.01 |
After reviewing the key financial ratios for Pharmaids Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Cash EPS (Rs.), as of Mar 25, the value is -3.14. This value is below the healthy minimum of 3. It has decreased from -2.87 (Mar 24) to -3.14, marking a decrease of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.51. It has increased from 4.28 (Mar 24) to 5.51, marking an increase of 1.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -3.59. This value is below the healthy minimum of 2. It has decreased from -3.50 (Mar 24) to -3.59, marking a decrease of 0.09.
- For PBIT / Share (Rs.), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 0. It has decreased from -3.98 (Mar 24) to -4.28, marking a decrease of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is -4.90. This value is below the healthy minimum of 0. It has decreased from -4.43 (Mar 24) to -4.90, marking a decrease of 0.47.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.83. This value is below the healthy minimum of 2. It has decreased from -3.36 (Mar 24) to -3.83, marking a decrease of 0.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.06. This value is below the healthy minimum of 2. It has decreased from -2.26 (Mar 24) to -3.06, marking a decrease of 0.80.
- For PBDIT Margin (%), as of Mar 25, the value is -65.06. This value is below the healthy minimum of 10. It has increased from -81.57 (Mar 24) to -65.06, marking an increase of 16.51.
- For PBIT Margin (%), as of Mar 25, the value is -77.61. This value is below the healthy minimum of 10. It has increased from -92.99 (Mar 24) to -77.61, marking an increase of 15.38.
- For PBT Margin (%), as of Mar 25, the value is -88.85. This value is below the healthy minimum of 10. It has increased from -103.37 (Mar 24) to -88.85, marking an increase of 14.52.
- For Net Profit Margin (%), as of Mar 25, the value is -69.44. This value is below the healthy minimum of 5. It has increased from -78.36 (Mar 24) to -69.44, marking an increase of 8.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -55.41. This value is below the healthy minimum of 8. It has decreased from -52.72 (Mar 24) to -55.41, marking a decrease of 2.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is -18.16. This value is below the healthy minimum of 15. It has decreased from -11.05 (Mar 24) to -18.16, marking a decrease of 7.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -16.56. This value is below the healthy minimum of 10. It has increased from -17.61 (Mar 24) to -16.56, marking an increase of 1.05.
- For Return On Assets (%), as of Mar 25, the value is -8.99. This value is below the healthy minimum of 5. It has decreased from -8.72 (Mar 24) to -8.99, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.50, marking an increase of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.07 (Mar 24) to 0.59, marking an increase of 0.52.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has decreased from 0.26 (Mar 24) to 0.18, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has decreased from 1.17 (Mar 24) to 0.77, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.35, marking a decrease of 0.50.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.13, marking an increase of 1.13.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -6.06. This value is below the healthy minimum of 3. It has increased from -7.86 (Mar 24) to -6.06, marking an increase of 1.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -5.42. This value is below the healthy minimum of 3. It has increased from -6.55 (Mar 24) to -5.42, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 271.01. It has increased from 182.39 (Mar 24) to 271.01, marking an increase of 88.62.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.94. This value exceeds the healthy maximum of 3. It has increased from 12.07 (Mar 24) to 13.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is -21.42. This value is below the healthy minimum of 5. It has decreased from -14.79 (Mar 24) to -21.42, marking a decrease of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 2.55 (Mar 24) to 4.08, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pharmaids Pharmaceuticals Ltd:
- Net Profit Margin: -69.44%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.56% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -18.16% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -5.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.35
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 50.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -69.44%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Unit 201, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013 | compliance@pharmaids.com http://www.pharmaids.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Shankarappa Nagaraja Vinaya Babu | Chairman, Non Ind & Non Exe Director |
| Ms. Mini Manikantan | Executive Director |
| Mr. Venu Madhava Kaparthy | Executive Director |
| Mr. Shreedhara Shetty | Non Exe.Non Ind.Director |
| Mr. Methuku Nagesh | Independent Director |
| Mr. P N Vijay | Independent Director |
| Mr. Mopperthy Sudheer | Independent Director |
FAQ
What is the intrinsic value of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd's intrinsic value (as of 10 October 2025) is 33.52 which is 28.68% lower the current market price of 47.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹166 Cr. market cap, FY2025-2026 high/low of 87.5/31.9, reserves of ₹24 Cr, and liabilities of 120 Cr.
What is the Market Cap of Pharmaids Pharmaceuticals Ltd?
The Market Cap of Pharmaids Pharmaceuticals Ltd is 166 Cr..
What is the current Stock Price of Pharmaids Pharmaceuticals Ltd as on 10 October 2025?
The current stock price of Pharmaids Pharmaceuticals Ltd as on 10 October 2025 is 47.0.
What is the High / Low of Pharmaids Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Pharmaids Pharmaceuticals Ltd stocks is 87.5/31.9.
What is the Stock P/E of Pharmaids Pharmaceuticals Ltd?
The Stock P/E of Pharmaids Pharmaceuticals Ltd is .
What is the Book Value of Pharmaids Pharmaceuticals Ltd?
The Book Value of Pharmaids Pharmaceuticals Ltd is 16.8.
What is the Dividend Yield of Pharmaids Pharmaceuticals Ltd?
The Dividend Yield of Pharmaids Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Pharmaids Pharmaceuticals Ltd?
The ROCE of Pharmaids Pharmaceuticals Ltd is 17.4 %.
What is the ROE of Pharmaids Pharmaceuticals Ltd?
The ROE of Pharmaids Pharmaceuticals Ltd is 16.3 %.
What is the Face Value of Pharmaids Pharmaceuticals Ltd?
The Face Value of Pharmaids Pharmaceuticals Ltd is 10.0.